NasdaqCM - Nasdaq Real Time Price USD

Mainz Biomed N.V. (MYNZ)

4.6700

+0.3900

+(9.11%)

At close: January 13 at 4:00:01 PM EST

Mainz Biomed partners with Quest for colorectal cancer screening test

The test leverages PCR technology to detect cancerous DNA in stool samples.

Medical Device Network 24 days ago

MYNZ
+9.11%
DGX
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz B

GlobeNewswire 25 days ago

MYNZ
+9.11%
DGX
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the closing of its previously announced follow-on offering of 1,367,521 units, with each unit consisting of one ordinary share (or prefunded warrant in lieu thereof) one Class A warrant to purchase one ordinary share, and one Class B warrant to purchase one o

GlobeNewswire 28 days ago

MYNZ
+9.11%
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 1,367,521 units, with each unit consisting of one ordinary share (or prefunded warrant in lieu thereof) one Series A warrant to purchase one ordinary share, and one series B warrant to purchase one ordinary share for gro

GlobeNewswire last month

MYNZ
+9.11%
Mainz Biomed Announces Stock Split

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024. The r

GlobeNewswire last month

MYNZ
+9.11%
The Oncology Bet Is Already Paying Off For Pfizer

With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs.

Benzinga last month

PFE

MRNA

MYNZ
+9.11%
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (“Thermo Fisher”), a world leader in supplying life sciences solutions and services. The collaboration agreement will enable Mainz B

GlobeNewswire 2 months ago

MYNZ
+9.11%
TMO
Mainz Biomed restructured operations, implemented cost reductions

In September 2024, Mainz Biomed (MYNZ) announced feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with additional average risk population. In October 2024, the Company made the strategic decision to focus its efforts on three key initiatives for the remainder of 2024 and into 2025 in order to maximize shareholder value. Those initiatives are: The continued growth of its ColoAlert business in Europe; Development of its

TipRanks 2 months ago

MYNZ
+9.11%
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular g

GlobeNewswire 2 months ago

MYNZ
+9.11%
Mainz Biomed Secures Additional $1.5M Funding

Mainz Biomed B.V. (MYNZ) has released an update. Mainz Biomed B.V. has entered into a supplemental agreement with YA II PN, LTD. for a fourth Pre-Paid Advance of $1.5 million, following three previous promissory notes totaling $14.3 million. The funds from this latest note are designated for working capital and general corporate purposes, ensuring the company’s continued operations without shareholder approval for issuance. The transaction is exempt from registration under the Securities Act, in

TipRanks 3 months ago

MYNZ
+9.11%
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-BadenBERKELEY, Calif. and MAINZ, Germany, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today increasing demand from existing and prospective laboratory partners for its enhanced ColoAlert product that has been launched in July 2024 and is currently being commercializ

GlobeNewswire 3 months ago

MYNZ
+9.11%
The Covid Era Tech Promises To Reinvent Cancer Treatment

Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. Both Moderna and Pfizer made history during the COVID-19 pandemic thanks to mRNA technology. Now, Moderna and Pfizer embarked on a journey to treat cancer with mRNA science. By using mRNA-based next-generation CRC screening tests, a much smaller and less known pharma player, Mainz Biomed N.V. (NASDAQ: MYNZ), is already redefining stan

Benzinga 3 months ago

PFE

MRNA

MYNZ
+9.11%
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today released a statement to shareholders highlighting its strategic plans for maximizing shareholder value, clinical developments, and its upcoming FDA trial anticipated for 2025, which aims to pave the way for entry into the U.S. market. Management believes 2025 will be a

GlobeNewswire 3 months ago

MYNZ
+9.11%
Pfizer Advances On Its Cancer Journey

On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024 Congress. Affecting as many as 9 million people across the globe, cancer cachexia is a life-threatening condition that causes cancer patients to lose appetite and consequently, weight. Paving The Way For The World’s First Treatment For Cancer Cachexia The mid-stage trial results showed that patients that

Benzinga 3 months ago

PFE

MRNA

MRK
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early DetectionBERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the

GlobeNewswire 3 months ago

MYNZ
+9.11%
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First AnalysisBERKELEY, Calif. and MAINZ, Germany, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the expansion of its collaboration with Liquid Biosciences to Mainz Biomed’s next-generation detection te

GlobeNewswire 4 months ago

MYNZ
+9.11%
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer

The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE) responded by slashing costs and shifting their focus to revolutionizing cancer treatment. Smaller pharma players are also making history when it comes to oncology. One such example is Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specialized in early cancer diagnostics. Last we

Benzinga 5 months ago

PFE

MYNZ
+9.11%
MRK
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today announced significant improvements to its ColoAlert product, currently being commercialized across Europe and in select international markets. These updates aim to enhance customer satisfaction and streamline lab operations. ColoAlert is a highly efficacious and easy-to-use, at-home detection test for col

GlobeNewswire 5 months ago

MYNZ
+9.11%
Mainz Biomed seeks FDA breakthrough device status for colorectal cancer test

The test reported a sensitivity of 97% for CRC and 88% for advanced precancerous lesions, with a specificity of 93%.

Medical Device Network 6 months ago

MYNZ
+9.11%
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense A recent clinical analysis of this new configuration demonstrates sensitivity for colorectal cancer of 97% and 88% for advanced adenomas, with specificity of 93% BERKELEY, Calif. and MAINZ, Germany, July 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular gene

GlobeNewswire 6 months ago

MYNZ
+9.11%

Performance Overview

Return	MYNZ	S&P 500
YTD	+2.41%	-1.20%
1-Year	+290.79%	+22.00%
3-Year	-71.03%	+23.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mainz Biomed N.V. (MYNZ)

Mainz Biomed partners with Quest for colorectal cancer screening test

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Mainz Biomed Announces Stock Split

The Oncology Bet Is Already Paying Off For Pfizer

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

Mainz Biomed restructured operations, implemented cost reductions

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Mainz Biomed Secures Additional $1.5M Funding

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

The Covid Era Tech Promises To Reinvent Cancer Treatment

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Pfizer Advances On Its Cancer Journey

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Mainz Biomed seeks FDA breakthrough device status for colorectal cancer test

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Performance Overview